| Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) (NCT06525675) | MedSIR | 2022-07-18 |
| Roll-over Study to Allow Continued Access to Ribociclib (NCT05161195) | Novartis Pharmaceuticals | 2022-07-07 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT04941365) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 |
| Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians (NCT05440929) | UNC Lineberger Comprehensive Cancer Center | 2022-07-07 |
| Comprehensive Outcomes for After Cancer Health (NCT05349227) | Pack Health | 2022-06-23 |
| Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor. (NCT05303129) | Centre Francois Baclesse | 2022-05-27 |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (NCT05227131) | MedSIR | 2022-05-15 |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (NCT05029999) | University of Texas Southwestern Medical Center | 2022-04-20 |
| Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (NCT05065411) | Veru Inc. | 2022-04-11 |
| A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway (NCT05331326) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-04-01 |
| Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (NCT05207709) | SOLTI Breast Cancer Research Group | 2022-03-28 |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (NCT05340413) | SOLTI Breast Cancer Research Group | 2022-03-25 |
| Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer (NCT05334459) | Ankara Oncology Research and Training Hospital | 2022-03-01 |
| D4 Choline Breast PET/CT (NCT04276272) | Imperial College London | 2022-02-24 |
| Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (NCT05217381) | MedSIR | 2022-02-22 |
| Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (NCT05486182) | GE Healthcare | 2022-02-08 |
| European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (NCT05043506) | Pfizer | 2022-02-08 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (NCT05143970) | Institut Paoli-Calmettes | 2022-01-21 |
| Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 (NCT04983238) | Byondis B.V. | 2022-01-10 |
| Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC (NCT05233696) | University of Colorado, Denver | 2022-01-04 |
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea (NCT05132101) | Pfizer | 2021-12-20 |
| Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m (NCT05141708) | Pfizer | 2021-12-17 |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period (NCT05135104) | Asociatia Oncohelp - Centrul de Oncologie Oncohelp | 2021-12-15 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (NCT05216432) | Relay Therapeutics, Inc. | 2021-12-08 |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer (NCT05176080) | Henan Cancer Hospital | 2021-12-08 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (NCT06570031) | Ono Pharmaceutical Co., Ltd. | 2021-11-09 |
| Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer (NCT05086731) | Emory University | 2021-10-22 |
| Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer (NCT05021900) | Rhizen Pharmaceuticals SA | 2021-10-13 |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (NCT04869943) | Veru Inc. | 2021-10-12 |
| Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer (NCT05090358) | Memorial Sloan Kettering Cancer Center | 2021-10-08 |
| Scalp Cooling in MBC (NCT04986579) | Dana-Farber Cancer Institute | 2021-10-07 |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868) | Rhizen Pharmaceuticals SA | 2021-10-05 |
| Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (NCT04720664) | Georgetown University | 2021-09-22 |
| Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab (NCT05346861) | Fudan University | 2021-09-15 |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (NCT05054374) | Memorial Sloan Kettering Cancer Center | 2021-09-14 |
| BRaziLian outcomE for metAStatic breasT Cancer (NCT05559528) | Hospital do Coracao | 2021-09-13 |
| A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer (NCT04872608) | Memorial Sloan Kettering Cancer Center | 2021-09-09 |
| Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer (NCT04990921) | University of Louisville | 2021-09-02 |
| Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor (NCT05361655) | Pfizer | 2021-09-01 |
| Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer (NCT04963595) | Zhiyong Yu | 2021-08-01 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (NCT04669587) | EnhancedBio USA Inc. | 2021-07-26 |
| Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients (NCT04608357) | Sunnybrook Health Sciences Centre | 2021-07-21 |
| Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone (NCT05012644) | Pfizer | 2021-07-16 |
| Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer (NCT06320392) | Ain Shams University | 2021-07-01 |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04924699) | Shanghai Miracogen Inc. | 2021-06-30 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778) | HiberCell, Inc. | 2021-06-08 |
| A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (NCT04740918) | Hoffmann-La Roche | 2021-06-07 |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer (NCT04872166) | Edgewood Oncology Inc. | 2021-06-07 |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. (NCT04733417) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-26 |
| Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer (NCT04573231) | University of Wisconsin, Madison | 2021-05-24 |
| Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NCT04370522) | Spanish Breast Cancer Research Group | 2021-05-21 |
| Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer (NCT04857619) | AstraZeneca | 2021-05-14 |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04965766) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-11 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (NCT04296942) | National Cancer Institute (NCI) | 2021-05-04 |
| A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer (NCT04699630) | SCRI Development Innovations, LLC | 2021-05-03 |
| Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (NCT04315233) | University of Utah | 2021-05-03 |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer (NCT04683679) | Memorial Sloan Kettering Cancer Center | 2021-04-21 |
| A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (NCT04734262) | Fudan University | 2021-04-01 |
| Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey (NCT04770129) | Turkish Oncology Group | 2021-03-22 |
| Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer (NCT04495309) | University Hospital Schleswig-Holstein | 2021-03-05 |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (NCT04703920) | University of Michigan Rogel Cancer Center | 2021-03-04 |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (NCT03749850) | UMC Utrecht | 2021-03-01 |
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. (NCT04796324) | Allarity Therapeutics | 2021-03-01 |
| Nurse AMIE for Echo Show: Randomized Control Trial (NCT04673019) | Milton S. Hershey Medical Center | 2021-02-02 |
| Feasibility of Fasting & Exercise in Pts With HR+ MBC (NCT04708860) | Dana-Farber Cancer Institute | 2021-01-15 |
| Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC (NCT05131841) | Zhejiang Cancer Hospital | 2021-01-04 |
| CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer (NCT07704801) | Sohag University | 2021-01-01 |
| Couples' QOL in Metastatic Breast Cancer (NCT05636943) | Fox Chase Cancer Center | 2021-01-01 |
| Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC (NCT04609540) | Shandong Cancer Hospital and Institute | 2021-01-01 |
| A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (NCT04538742) | AstraZeneca | 2020-12-28 |
| A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (NCT04556773) | AstraZeneca | 2020-12-17 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel. (NCT04671615) | Pfizer | 2020-12-06 |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (NCT04639986) | Gilead Sciences | 2020-11-23 |
| Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer (NCT04497285) | SOLTI Breast Cancer Research Group | 2020-10-20 |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (NCT03685331) | Abramson Cancer Center at Penn Medicine | 2020-10-15 |
| Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer (NCT05206656) | Hunan Cancer Hospital | 2020-10-09 |
| First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (NCT04408118) | MedSIR | 2020-10-05 |
| Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (NCT04432454) | Sermonix Pharmaceuticals Inc. | 2020-09-29 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer (NCT04352777) | Duke University | 2020-09-14 |
| Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer (NCT03982004) | Washington University School of Medicine | 2020-09-14 |
| To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer (NCT04660435) | Fondazione Sandro Pitigliani | 2020-09-01 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941) | Royal Marsden NHS Foundation Trust | 2020-08-11 |
| Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression (NCT04251169) | SOLTI Breast Cancer Research Group | 2020-07-21 |
| Atezolizumab Plus CArboplatin Plus Nab-paclitaxel (NCT05266937) | Consorzio Oncotech | 2020-07-03 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer (NCT04354233) | Centre Leon Berard | 2020-06-24 |
| Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention. (NCT04173897) | University of Leeds | 2020-06-06 |
| Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients (NCT04262518) | Outcomes4Me | 2020-06-01 |
| Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer (NCT04367090) | Jiangsu HengRui Medicine Co., Ltd. | 2020-05-28 |
| To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer (NCT04332549) | Sun Pharma Advanced Research Company Limited | 2020-04-27 |
| ImmunoBreast - A Phase Ib Study (NCT04609215) | Henrik Ditzel | 2020-04-21 |
| A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors (NCT05141240) | Novartis Pharmaceuticals | 2020-04-15 |
| Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine (NCT04389073) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-04-01 |
| Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer (NCT04134884) | Kathy Miller | 2020-04-01 |
| Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (NCT04293276) | Henan Cancer Hospital | 2020-04-01 |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy (NCT04030728) | Onco Medical Consult GmbH | 2020-03-01 |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (NCT04253561) | SOLTI Breast Cancer Research Group | 2020-02-25 |